Nearly 40,000 eye drops recalled nationwide over possible contamination
Prestige Brand Holdings is recalling 39,060 bottles of certain Clear Eyes drops over sterility concerns, according to a Food and Drug Administration report.
PBH - Prestige Consumer Healthcare Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$81.67
DETAILS
HIGH:
$93.00
LOW:
$66.00
MEDIAN:
$86.00
CONSENSUS:
$81.67
UPSIDE:
58.32%
Stock News
Amylyx: Upgraded To Strong Buy On LUCIDITY Outcome, Avexitide, And 2026 Catalysts
Amylyx Pharmaceuticals, Inc. is upgraded to Strong Buy after positive phase 3 LUCIDITY results for avexitide in post-bariatric hypoglycemia [PBH]. Avexitide met its primary endpoint, achieving a 55% reduction in severe hypoglycemic events, with strong statistical significance and a favorable safety profile. Key catalysts include an NDA submission for avexitide in PBH by end-2026 and medical data presentation in 2026; expansion into long-acting GLP-1 antagonist AMX0318 is underway.
PBH or SYK: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Products stocks have likely encountered both Prestige Consumer Healthcare (PBH) and Stryker (SYK). But which of these two stocks presents investors with the better value opportunity right now?
Premium Brands Q2 Earnings Call Highlights
Premium Brands TSE: PBH said its revised 2026 outlook reflects timing shifts in U.S. customer programs and the exit of a low-margin Ontario facility, rather than a deterioration in the company's underlying operating assumptions.
California State Teachers Retirement System Has $3.40 Million Position in Prestige Consumer Healthcare Inc. $PBH
California State Teachers Retirement System boosted its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE: PBH) by 21.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 57,310 shares of the company's stock after acquiring an additional 10,117 shares during
Prestige Consumer Healthcare Q1 Earnings Call Highlights
Prestige Consumer Healthcare NYSE: PBH reported first-quarter fiscal 2027 revenue growth of 6.5%, supported by broad-based category strength, the initial contribution from its Breathe Right acquisition and retailer order timing. The company raised its reported full-year outlook to incorporate Breathe Right and LaCorium Health while maintaining its prior outlook for organic revenue growth.
Prestige Consumer Healthcare Inc. (PBH) Q1 2027 Earnings Call Transcript
Prestige Consumer Healthcare Inc. (PBH) Q1 2027 Earnings Call Transcript
Prestige Consumer Healthcare (PBH) Q1 Earnings and Revenues Surpass Estimates
Prestige Consumer Healthcare (PBH) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.89 per share. This compares to earnings of $0.95 per share a year ago.
Prestige Consumer Healthcare Inc. Reports Fiscal 2027 First Quarter Results
TARRYTOWN, N.Y., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its first quarter fiscal 2027 ended June 30, 2026.
Prestige Consumer Healthcare Inc. $PBH Shares Sold by Bank of New York Mellon Corp
Bank of New York Mellon Corp cut its position in shares of Prestige Consumer Healthcare Inc. (NYSE: PBH) by 4.2% in the undefined quarter, according to the company in its most recent disclosure with the SEC. The fund owned 311,341 shares of the company's stock after selling 13,557 shares during the quarter. Bank
Dimensional Fund Advisors LP Acquires 91,710 Shares of Prestige Consumer Healthcare Inc. $PBH
Dimensional Fund Advisors LP increased its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE: PBH) by 3.6% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,672,777 shares of the company's stock after purchasing an additional 91,710 shares during the quarter.
Ariel Small/Mid Cap Value Q2 2026 Portfolio Activity
The Ariel Small/Mid Cap Value Composite rose +15.08% gross of fees (+14.95% net of fees) in the quarter, falling short of both the Russell 2500 Value Index's +18.50% return and the +20.26% gain posted by the Russell 2500 Index. Live entertainment, media, and technology company, Sphere Entertainment Co. was the top contributor during the quarter on solid earnings and improving operating fundamentals. Shares of Prestige Consumer Healthcare moved lower following disappointing earnings, driven primarily by ongoing supply constraints in its eye care segment and extended lead times in the Middle East.
Fifth Third Bancorp Purchases 28,699 Shares of Prestige Consumer Healthcare Inc. $PBH
Fifth Third Bancorp boosted its position in Prestige Consumer Healthcare Inc. (NYSE: PBH) by 8,130.0% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 29,052 shares of the company's stock after buying an additional 28,699 shares during the quarter. Fifth Third Bancorp
Bessemer Group Inc. Acquires 64,760 Shares of Prestige Consumer Healthcare Inc. $PBH
Bessemer Group Inc. raised its holdings in Prestige Consumer Healthcare Inc. (NYSE: PBH) by 20.9% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 374,691 shares of the company's stock after buying an additional 64,760 shares during the period. Bessemer Group Inc. owned
John Rogers Increases Stake in Prestige Consumer Healthcare Inc
On June 30, 2026, John Rogers (Trades, Portfolio) executed a notable transaction involving Prestige Consumer Healthcare Inc (PBH). The transaction saw an additi
Is the Options Market Predicting a Spike in Prestige Consumer Healthcare Stock?
Investors need to pay close attention to PBH stock based on the movements in the options market lately.
Prestige Consumer Healthcare Inc. Completes Acquisition of LaCorium Health, Prices $400 Million Senior Notes Offering, and Announces First Quarter Fiscal 2027 Earnings Results Date
TARRYTOWN, N.Y., July 06, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) (“Prestige”) today announced that it has closed the previously announced acquisition of LaCorium Health (“LaCorium”), priced a private offering of $400 million in senior notes, and will report its first quarter fiscal 2027 results on August 6, 2026.
Alphabet Joined the Dow and Became a Top Holding in Berkshire Hathaway's Portfolio. But This Stock Could Be an Even Better Buy.
This under-the-radar healthcare stock just made its biggest acquisition ever -- and it could easily outperform many of Wall Street's favorite names.
Prestige Consumer Healthcare Inc. Announces Offering of $400 Million Senior Notes
TARRYTOWN, N.Y., June 30, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE: PBH) (the “Company”) announced today that its wholly-owned subsidiary, Prestige Brands, Inc. (“Prestige Brands”), intends to offer, subject to market and other conditions, up to $400 million in aggregate principal amount of new senior notes due 2034 (the “notes”) in a private offering. The notes will be senior unsecured obligations of Prestige Brands and will be guaranteed by the Company and certain of its domestic subsidiaries.
Prestige Consumer Healthcare Inc. (PBH) Clear Eyes® and Pillar5 Problems Drive Stock Lower, HBSS Investigating
SAN FRANCISCO, June 25, 2026 /PRNewswire/ -- Investors in Prestige Consumer Healthcare (NYSE: PBH) saw the price of their shares fall over 11% on May 14, 2026 after the company revealed significant revenue declines and production problems driving the company's disappointing Q4 2026 financial results. The surprise developments have prompted national shareholder rights firm Hagens Berman to open an investigation into whether, before May 14, Prestige was sufficiently transparent regarding its ability to remediate supply chain constraints and, if not, whether the company violated the federal securities laws.
Price Targets
Prestige Consumer price target lowered to $66 from $70 at Jefferies
$66.00
(was $64.18)
Keith Devas
·
Jefferies
Prestige Consumer price target lowered to $71 from $75 at Jefferies
$71.00
(was $61.95)
Jefferies
Presitge Brands (PBH) PT Raised to $86 at Canaccord Genuity
$86.00
(was $74.58)
SUsan Anderson
·
Canaccord Genuity
DA Davidson Defending Presitge Brands (PBH), Uprades to Buy
$93.00
(was $68.12)
Linda Bolton Weiser
·
D.A. Davidson
Canaccord Genuity Initiates Coverage On Prestige Consumer with Buy Rating, Announces Price Target of $71
$71.00
(was $58.35)
Canaccord Genuity